Peptide OXY-CJC1295 (5 mg) OxyPharma

Catalogue entry: Peptide OXY-CJC1295 (5 mg) OxyPharma. Labelled content: 5 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

This entry records material described by its source as CJC-1295 without sufficient confirmation of DAC status. The name alone does not establish an albumin-binding analogue, modified GRF or another related preparation. Assigning a duration of action on the basis of that name would add a fact that the product documentation has not established.

What the research measured

Teichman and colleagues studied long-acting CJC-1295 in healthy adults in 2006. The reported GH and IGF-I responses concern that defined investigational substance. They should not be transferred to every product carrying a similar label. FDA's review of CJC-related substances also makes distinctions between active moieties relevant to identity assessment.

Sporting claims and limitations

Comparison with confirmed CJC-1295 DAC or Sermorelin is useful precisely because the molecular differences matter. A claimed recovery or muscle-growth effect cannot resolve the unidentified structure. Endocrine and metabolic risks likewise cannot be predicted reliably from an unspecified source name. Combining uncertain material with Ipamorelin adds another layer of uncertainty rather than verifying either ingredient.

Product identity and documentation

Before interpreting an analytical certificate, check the full peptide sequence, DAC modification if any, chemical form and actual formulation. A lot number links a report to a sample only if the substance tested is clearly identified. The selected content describes the source listing; it does not close these specification gaps. This distinction keeps the catalogue record honest while allowing later verified information to be added.